These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 36841031)

  • 41. [Research Advances of Immunotherapy of Exosome PD-L1 
in Non-small Cell Lung Cancer].
    Wang N; Song X
    Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):689-695. PubMed ID: 36172735
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
    Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
    Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.
    Ripp J; Hentzen S; Saeed A
    Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma.
    Saha D; Martuza RL; Rabkin SD
    Immunotherapy; 2018 Jul; 10(9):779-786. PubMed ID: 30008259
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma.
    Seremet T; Planken S; Schwarze JK; Jansen Y; Vandeweerd L; van den Begin R; Tsechelidis I; Lienard D; Del Marmol V; Neyns B
    Melanoma Res; 2019 Feb; 29(1):85-88. PubMed ID: 30211812
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sphingosine kinase 1 promotes tumor immune evasion by regulating the MTA3-PD-L1 axis.
    Lau P; Zhang G; Zhao S; Liang L; Zhang H; Zhou G; Hung MC; Chen X; Liu H
    Cell Mol Immunol; 2022 Oct; 19(10):1153-1167. PubMed ID: 36050478
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes
    Larson C; Oronsky B; Reid T
    Am J Cancer Res; 2022; 12(7):3141-3147. PubMed ID: 35968324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
    Nguyen HM; Bommareddy PK; Silk AW; Saha D
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):971-980. PubMed ID: 34033895
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model.
    Vitale M; Scialò F; Passariello M; Leggiero E; D'Agostino A; Tripodi L; Gentile L; Bianco A; Castaldo G; Cerullo V; De Lorenzo C; Pastore L
    Front Oncol; 2022; 12():902190. PubMed ID: 35669438
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma.
    Kuang X; Wang Z; Luo Z; He Z; Liang L; Gao Q; Li Y; Xia K; Xie Z; Chang R; Wang Y; Liu Y; Zhao S; Su J; Wang Y; Situ W; Chen M; Zhao Y; Chen X; Xie H; Liu H
    J Colloid Interface Sci; 2022 Jun; 616():189-200. PubMed ID: 35203032
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Modifying CAR-T cells with anti-checkpoints in cancer immunotherapy: A focus on anti PD-1/PD-L1 antibodies.
    Najafi S; Mortezaee K
    Life Sci; 2024 Feb; 338():122387. PubMed ID: 38154609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
    Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
    Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving the synergistic combination of programmed death-1/programmed death ligand-1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment.
    Mudassar F; Shen H; Cook KM; Hau E
    J Med Imaging Radiat Oncol; 2022 Jun; 66(4):560-574. PubMed ID: 35466515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.